Protein Serine/Threonine Kinases in Neurodegenerative Disorders
- 1 Edición - 15 de junio de 2026
- Última edición
- Editores: Heba Mohamed Mansour, Aiman Saad El-Khatib
- Idioma: Inglés
Protein Serine/Threonine Kinases in Neurodegenerative Disorders provides a comprehensive overview of protein serine/threonine kinases (STKs) in health and disease. It also di… Leer más
Descripción
Descripción
Protein Serine/Threonine Kinases in Neurodegenerative Disorders provides a comprehensive overview of protein serine/threonine kinases (STKs) in health and disease. It also discusses protein kinase inhibitors and their potential role in modulating and treating neurodegenerative diseases. This book begins with an introduction to protein kinases and inhibitors, followed by detailed discussions on different types of kinases, including protein kinase C (PKC), AMP-activated protein kinase (AMPK), death-associated protein kinase 1 (DAPK1), cyclin-dependent kinases (CDKs), glycogen synthase kinases (GSKs), Rho-associated protein kinase (ROCK), microtubule affinity regulating kinases (MARKs), mammalian target of rapamycin (mTOR), leucine-rich repeat kinase 2 (LRRK2), PTEN-induced kinase 1 (PINK1), and dual-specificity tyrosine phosphorylation-regulated kinase (DYRK), and their roles in neurodegenerative disease, potential inhibitors, and therapeutic
mechanisms.
This book features 23 chapters written by renowned experts in the field of kinases. It explores novel targets modulated by protein kinases, including noncoding RNAs (ncRNAs) and mitogen-activated protein kinases (MAPKs) activated by tyrosine receptor kinases, and their roles in neurodegeneration. It also discusses the nexus between glycogen synthase kinases (GSKs) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their role of metabolic regulation in neurodegeneration. The modulatory effects of protein kinase B (PKB/AKT) pathways in various neurodegenerative disorders, particularly Parkinson’s disease, are also examined. This book sheds light on bioactive compounds from natural products that target kinases. This book explains the role of different kinases in various pathogenic pathways and mechanisms involved in neurodegeneration, including regulated cell death, autophagy, synaptic dysfunction, and neuroinflammation. It also discusses splicing kinases in regulating splicing factor phosphorylation and details how aberrant kinase activity leads to splicing defects that contribute to neurodegenerative pathologies. This book emphasizes bridging laboratory research with clinical applications, focusing on translational opportunities. It includes insights from FDA regulatory experts on therapeutic applications and safety considerations of targeting kinases, highlighting the
importance of balancing efficacy and safety, particularly in relation to drug-induced liver injury associated with kinase inhibitors. Finally, this book discusses the obstacles and opportunities for the potential repositioning of protein kinase inhibitors in neurodegenerative disorders
Puntos claves
Puntos claves
- Explores how kinases regulate cellular processes and contribute to neurodegenerative disorders
- Highlights emerging therapies targeting these kinases, empowering readers with actionable knowledge
- Includes case studies demonstrating kinase-targeted strategies in neurodegenerative disorders
De interès para
De interès para
Índice
Índice
2. Protein kinase C (PKC) in Neurodegenerative disorders
3. AMP-activated protein kinase (AMPK) in neurodegenerative disorders
4. Death-associated protein kinase 1 (DAPK1) in neurodegenerative disorders
5. The mitogen-activated protein kinases (MAPKs) activated by tyrosine receptor kinases (Trk receptors for neurotrophin) and their roles in neurodegeneration
6. Cyclin-dependent kinases (CDKs) in neurodegenerative disorders
7. Unlocking the Potential of GSK-3β Inhibitors in Neurodegenerative Disease Prognosis: Insights from Glucagon-like Peptide-1 Receptor Agonist Effects
8. Rho-Associated Coiled-Coil-Containing Protein Kinase (ROCK) in neurodegenerative disorders
9. Microtubule Affinity-Regulating Kinases (MARKs) in neurodegenerative disorders
10. Mammalian target of Rapamycin (mTOR) in neurodegenerative disorders
11. Leucine-Rich Repeat Kinase 2 (LRRK2): A Potential Target in Parkinson’s Disease and Beyond
12. PTEN-induced kinase 1 (PINK1) in neurodegenerative disorders
13. Dual-specificity Tyrosine phosphorylation-Regulated Kinase-1A (DYRK1A) in Neurodegenerative disorders
14. AKT pathway as therapeutic target in neurodegenerative diseases: mechanisms and implications
15. Targeting AKT pathways: A potential therapeutic target for Parkinson's disease
16. Non-coding RNAs Regulating Serine/Threonine Kinases in Neurodegeneration
17. Protein serine/threonine signaling pathways: Opportunities and translational perspectives
18. Natural Products in Neurodegenerative Diseases: Role of Serine/Threonine Kinases
19. Targeting autophagy-related serine/threonine kinases to combat neurodegenerative disorders
20. Targeting regulated cell death-related serine/threonine kinases to combat neurodegenerative disorders
21. Splicing Kinases in Neuronal Health and Neurodegeneration
22. Balancing Efficacy and Safety: Protein Kinase Inhibitors and Drug-Induced Liver Injury
23. Targeting serine/threonine kinases: Therapeutic innovations for neurodegenerative disorders
1. Protein serine/threonine kinases: An overview
2. Protein kinase C (PKC) in Neurodegenerative disorders
3. AMP-activated protein kinase (AMPK) in neurodegenerative disorders
4. Death-associated protein kinase 1 (DAPK1) in neurodegenerative disorders
5. The mitogen-activated protein kinases (MAPKs) activated by tyrosine receptor kinases (Trk receptors for neurotrophin) and their roles in neurodegeneration
6. Cyclin-dependent kinases (CDKs) in neurodegenerative disorders
7. Unlocking the Potential of GSK-3β Inhibitors in Neurodegenerative Disease Prognosis: Insights from Glucagon-like Peptide-1 Receptor Agonist Effects
8. Rho-Associated Coiled-Coil-Containing Protein Kinase (ROCK) in neurodegenerative disorders
9. Microtubule Affinity-Regulating Kinases (MARKs) in neurodegenerative disorders
10. Mammalian target of Rapamycin (mTOR) in neurodegenerative disorders
11. Leucine-Rich Repeat Kinase 2 (LRRK2): A Potential Target in Parkinson’s Disease and Beyond
12. PTEN-induced kinase 1 (PINK1) in neurodegenerative disorders
13. Dual-specificity Tyrosine phosphorylation-Regulated Kinase-1A (DYRK1A) in Neurodegenerative disorders
14. AKT pathway as therapeutic target in neurodegenerative diseases: mechanisms and implications
15. Targeting AKT pathways: A potential therapeutic target for Parkinson's disease
16. Non-coding RNAs Regulating Serine/Threonine Kinases in Neurodegeneration
17. Protein serine/threonine signaling pathways: Opportunities and translational perspectives
18. Natural Products in Neurodegenerative Diseases: Role of Serine/Threonine Kinases
19. Targeting autophagy-related serine/threonine kinases to combat neurodegenerative disorders
20. Targeting regulated cell death-related serine/threonine kinases to combat neurodegenerative disorders
21. Splicing Kinases in Neuronal Health and Neurodegeneration
22. Balancing Efficacy and Safety: Protein Kinase Inhibitors and Drug-Induced Liver Injury
23. Targeting serine/threonine kinases: Therapeutic innovations for neurodegenerative disorders
Detalles del producto
Detalles del producto
- Edición: 1
- Última edición
- Publicado: 15 de junio de 2026
- Idioma: Inglés
Sobre los editores
Sobre los editores
HM
Heba Mohamed Mansour
Heba Mohamed Mansour, Ph.D. is currently the Manager of the Innovative Products' Technical Evaluation Unit at the Central Administration of Biological, Innovative Products, and Clinical Studies (Bio-Inn) at the Egyptian Drug Authority (EDA). She is a topic leader in the ICH working group (EWG S13), specializing in non-clinical safety assessments of oligonucleotide-based therapeutics (ONTs). Heba received a PhD degree in pharmacology and toxicology from the Faculty of Pharmacy, Cairo University in 2024. She also received a diploma in environmental health from Ajloun University, Jordan. Her expertise encompasses a profound understanding of diverse cell death modalities in neurodegeneration and the exploration of potential drug repositioning strategies involving anti-cancer kinase inhibitors for neurodegenerative disorders. Her contributions extend to numerous research articles, prestigious international journal publications, book chapters, books, and comprehensive review articles, solidifying her interest in the field.
Scopus Author ID: 57222590031
Orchid ID: 0000-0001-7102-7305
AE
Aiman Saad El-Khatib
Aiman Saad El-Khatib, Ph.D. is a Professor of Pharmacology and Toxicology in the Faculty of Pharmacy, Cairo University since May 2002. He is a former vice president of Egyptian Drug Authority (EDA). He held several leadership positions in Cairo University, including Vice President for Graduate Studies and Research Affairs, Dean of Faculty of Pharmacy, Vice Dean for Education and Students Affairs, as well as Vice Dean for Community Service and Environment Development. Additionally, he held the post of Assistant Minister of Health and Population for Pharmaceutical Affairs. His primary research area of interest is the investigation of the pharmacological properties of various drugs, including natural products on the gastrointestinal tract, cardiovascular, and central nervous systems. He published numerous articles in international journals. His awards include Cairo University Scientific Research Fosterage in the field of Theoretical and Applied Biological Sciences in 2004 and Silver and Gold Medal of Merit from the Egyptian Syndicate of Pharmacists in 2004 and 2005.
Scopus Author ID: 7003395602
Orchid ID: 0000-0002-2074-8337